Compare AZZ & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AZZ | ICUI |
|---|---|---|
| Founded | 1956 | 1984 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.7B |
| IPO Year | 1994 | 1995 |
| Metric | AZZ | ICUI |
|---|---|---|
| Price | $132.77 | $152.06 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 5 |
| Target Price | $118.00 | ★ $179.50 |
| AVG Volume (30 Days) | 131.5K | ★ 218.3K |
| Earning Date | 04-08-2026 | 01-01-0001 |
| Dividend Yield | ★ 0.60% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 9.97 | 0.66 |
| Revenue | $1,061,817,000.00 | ★ $2,382,046,000.00 |
| Revenue This Year | $5.53 | N/A |
| Revenue Next Year | $5.59 | N/A |
| P/E Ratio | ★ $13.32 | $229.24 |
| Revenue Growth | ★ 14.53 | 5.44 |
| 52 Week Low | $70.90 | $107.02 |
| 52 Week High | $141.18 | $164.35 |
| Indicator | AZZ | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 60.56 | 53.83 |
| Support Level | $124.97 | $140.66 |
| Resistance Level | $141.18 | $155.90 |
| Average True Range (ATR) | 3.63 | 5.53 |
| MACD | 0.23 | -0.46 |
| Stochastic Oscillator | 54.34 | 75.30 |
AZZ Inc is a provider of galvanizing and a variety of metal coating solutions and coil coating solutions to a broad range of end markets in North America. The company's operating segment consists of Metal Coatings, Precoat Metals, and Infrastructure Solutions. The company generates the majority of its revenue from the Precoat Metals segment, which provides coil coating application of protective and decorative coatings and related value-added downstream processing for steel and aluminum coils. Geographically, the company generates the majority of its revenue from the United States.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.